Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (BMY) expanded its Champions in Care campaign with a planned $1 million grant program for medically underserved communities.
Now in its second year, the initiative will award grants to nonprofit organizations supporting these communities across the United States. Healthcare professionals can nominate organizations anonymously, with nominations due November 30, 2026. Nomination does not guarantee funding. The campaign will also include social, digital and live medical meeting activities through the remainder of the year.
Bristol Myers Squibb (NYSE: BMY) received FDA approval to expand CAMZYOS treatment to adults and pediatric patients with symptomatic obstructive hypertrophic cardiomyopathy. The indication covers patients weighing 30 kg (66 lbs) or more and aims to improve functional capacity and symptoms.
Approval was based on Phase 3 SCOUT-HCM, which enrolled 44 patients aged 12 to <18 years. At Week 28, the primary endpoint showed a statistically significant reduction in the pressure gradient across the heart’s obstructed outflow tract during the Valsalva maneuver: the adjusted difference versus placebo was −48.0 mmHg (P<0.0001). No patients had left ventricular ejection fraction, a measure of pumping function, below 50%, and no adverse events caused treatment discontinuation. Serious adverse events occurred in two patients in each group. CAMZYOS carries a boxed warning for heart failure and requires monitoring and restricted access.
Bristol Myers Squibb (BMY) reported Phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with ZENBEXUS-based treatment. Among 420 evaluable patients at a median follow-up of 15.7 months, ZENBEXUS with daratumumab and dexamethasone achieved this endpoint in 41.1%, versus 20.7% with daratumumab, bortezomib and dexamethasone (p<0.0001). Overall response rates were 88.9% and 76.1%, respectively.
Grade 3/4 neutropenia occurred in 84.3% versus 11.3%, while grade 3/4 infections occurred in 39.2% versus 21.6%. Any-grade peripheral sensory neuropathy occurred in 12.3% versus 42.6%. The ZENBEXUS combination received accelerated FDA approval on August 13 for adults with multiple myeloma after at least one prior treatment line including a proteasome inhibitor and an immunomodulatory agent. Progression-free survival, the other primary endpoint, remains under evaluation in a confirmatory cohort of 800.
Bristol Myers Squibb (BMY) plans to announce its third quarter 2026 financial results on Thursday, October 29, 2026, followed by a conference call at 8:00 a.m. ET for the investment community.
A live audio webcast and related presentation materials will be accessible on the company’s Investor Relations website. A replay of the webcast will be made available on the same site approximately three hours after the call concludes.
Bristol Myers Squibb (BMY) reported two-year Phase 3 POETYK PsA-2 open-label extension data showing durable efficacy and consistent safety for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.
Among patients treated continuously with Sotyktu, Week 104 ACR20/50/70 response rates were 76.2%/52.6%/34.6% (observed) and 65.3%/44.9%/29.4% (NRI), with Minimal Disease Activity rates of 51.2% (observed) and 43.7% (NRI). Patients switched from placebo to Sotyktu at Week 16 achieved similar Week 104 ACR20/50/70 responses of 76.9%/54.6%/37.7% (observed) and 69.3%/49.2%/33.9% (NRI). Safety through Week 104 was in line with prior PsA-2 and long-term psoriasis data, with adverse events in 86.6% of 604 patients, serious adverse events in 12.6% and discontinuations due to adverse events in 7.6%.
Bristol Myers Squibb (BMY)/b) declared a quarterly dividend of $0.63 per share on its $0.10 par value common stock. The dividend will be paid on November 2, 2026 to shareholders who are on record at the close of business on October 2, 2026.
Bristol Myers Squibb (BMY) reported positive topline Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel) in quadruple-class exposed relapsed and refractory multiple myeloma.
The single-arm, open-label study met its primary endpoint, showing a statistically significant and clinically meaningful overall response rate in adults who had received four or more prior lines of therapy including IMiD, PI, anti‑CD38 and a BCMA‑targeted therapy. Key secondary endpoints of complete response rate after four or more prior lines and both overall and complete response rates after three or more prior lines were also met.
The safety profile of arlo-cel was consistent with other CAR T cell and GPRC5D‑targeting therapies. Arlo-cel is a potential first‑in‑class autologous GPRC5D‑directed CAR T designed as a single‑infusion treatment, aiming to eliminate GPRC5D‑expressing myeloma cells even after prior BCMA‑directed therapy. Full data will be presented at a future medical meeting.
Bristol Myers Squibb (NYSE: BMY) reported up to five-year results from the EXPLORER-LTE cohort of the MAVA-LTE study of Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) at ESC Congress 2026. The single-arm, open-label extension enrolled 231 patients who completed EXPLORER-HCM.
At 252 weeks, mean resting LVOT gradient fell by 38.7 mm Hg and Valsalva LVOT gradient by 55.6 mm Hg, with 97.4% of patients achieving Valsalva LVOT gradient ≤30 mm Hg. According to Bristol Myers Squibb, 69.6% improved by ≥1 NYHA class and 59.2% were asymptomatic, while mean LVEF decreased by 10.2% yet remained within the normal range. No new safety signals were observed versus EXPLORER-HCM.
Additional COLLIGO-HCM real-world data and a German registry analysis showed symptom improvement and LVOT obstruction reduction consistent with clinical trials. Camzyos is approved in more than 60 countries and has been prescribed to over 25,000 U.S. patients, but carries a boxed warning for heart failure risk and is available only via the CAMZYOS REMS Program.
Bristol Myers Squibb (NYSE:BMY) received U.S. FDA accelerated approval for ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) to treat adults with multiple myeloma after ≥1 prior therapy including a proteasome inhibitor and an immunomodulatory agent.
Approval is based on Phase 3 EXCALIBER-RRMM results, where ZDd achieved minimal residual disease (MRD)-negative complete response in 41% of patients versus 21% with daratumumab, bortezomib and dexamethasone (DVd), marking the first FDA approval in relapsed/refractory multiple myeloma based on MRD-negative CR. ZENBEXUS is the first FDA-approved CELMoD (cereblon-modulating protein degrader). Continued approval may depend on confirmatory evidence of clinical benefit, with progression-free survival still under evaluation. The drug carries boxed warnings for embryo-fetal toxicity and serious venous and arterial thromboembolism, is contraindicated in pregnancy, and is available only via the ZENBEXUS REMS program due to safety risks including severe neutropenia, infections, and a 4.9% rate of fatal adverse reactions in the trial.
Atrium Therapeutics (Nasdaq: RNA) announced it has earned a $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) after delivering a second lead RNA-based compound for an undisclosed cardiovascular indication under their global licensing and research collaboration.
According to Atrium Therapeutics, the BMS agreement includes eligibility for up to approximately $1.35 billion in research and development milestones, up to approximately $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities arising from the collaboration. Atrium is also advancing ATR 1072 for PRKAG2 syndrome into the Corventis Phase 1/2 trial following recent FDA IND clearance, and maintains a pipeline including ATR 1086 for PLN cardiomyopathy and two additional rare cardiomyopathy programs.